Introduction: Beta2-adrenergic agonists are a class of drugs used as primary treatment for respiratory diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD). The classification is based on the onset and duration of action of beta 2 agonists. The classes are divided into short-acting beta agonists (SABAs), long-acting beta agonists (LABAs), and more recently, ultra-long-acting beta agonists (ULTRA-LABAs). As the names suggest, SABAs with a shorter half-life are used for immediate relief of symptoms.
Materials and methods: Observational study of the type of cross-sectional study. This study targeted patients attending Damascus Hospital. The sample was selected randomly, and about (106) patients were selected who met specific acceptance criteria, the most important of which was the presence of sufficient information in the file, while all patients were excluded according to specific exclusion criteria. Place of study: Damascus Hospital. Study period: from 2/12/2023 until 5/22/2023.
Results: Our study concluded that there is a statistically significant relationship between the irregular use of beta2 agonists and an increase in the incidence of oral mycoses among the sample members. There is a correlation between the irregular use of beta-2 agonists and the increased incidence of ventricular arrhythmias among the sample. There is a statistically significant correlation between the irregular use of beta-agonists and the increased incidence of tachycardia and palpitations among the sample. There is a statistically significant relationship between irregular use of beta2 agonists and an increased incidence of high blood sugar in the sample. There is a statistically significant correlation between the irregular use of beta-agonists and the increased incidence of reflex bronchospasm among the sample. And that there is a statistically significant correlation between the irregular use of beta-2 agonists and the increased need for oral admissions among the respondents. There is a statistically significant relationship between infrequent use of beta-2 agonists and serious sequelae of side-effects of beta-2 agonists.
Recommendations: Healthcare providers should raise awareness about the importance of adherence to and careful use of short-acting beta2-agonists and to avoid uncontrolled excessive use. Periodic evaluation of the asthmatic condition and the extent of strict adherence to the treatment plan and the prescribed doses should be done. Increasing awareness of asthma patients about the side effects of beta-2 agonists and symptoms of intoxication, and urging them to see a doctor when any of them appear. And further cohort studies on the role of excessive use of beta-agonists and mortality risk in patients with asthma.